Establishing and expanding the indications for proton and particle therapy

References

• Larsson B, Leksell L, Rexed B, Sourander P. Effect of high energy protons on the spinal cord. Acta Radiol 1959;51:52–64.
   PubMed Web of Science ®Google Scholar
• Falkmer S, Fors B, Larsson B, Lindell A, Näslund J, Stenson S. Pilot study on proton irradiation of human carcinoma. Acta Radiol 1962;58:33–51.
   PubMed Web of Science ®Google Scholar
• Glimelius B. A new volume of Acta Oncologica2011;50:3–5.
   Google Scholar
• Brahme A. Physical and biologic aspects on the optimum choice of radiation modality. Acta Radiol Oncol 1982;21:469–79.
   PubMed Web of Science ®Google Scholar
• Svensson H, Ringborg U, Näslund I, Brahme A. Development of light ion therapy at the Karolinska Hospital and Institute. Radiother Oncol 2004;73(Suppl 2):206–10.
   Web of Science ®Google Scholar
• Brahme A. Accurate description of the cell survival and biological effect at low and high doses and LET’s. J Radiat Res 2011;52:389–407.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ask A, Bjelkengren G, Björk-Eriksson T, Blomquist E, Johansson B, . Number of patients potentially eligible for proton therapy. Acta Oncol 2005;44:836–49.
   PubMed Web of Science ®Google Scholar
• Nystrøm H, Blomqvist E, Høyer M, Montelius A, Muren LP, Nilsson P, . Particle therapy – A next logical step in the improvement of radiotherapy. Acta Oncol 2011;50:741–4.
   PubMed Web of Science ®Google Scholar
• Schippers, JM, Lomax AJ. Emerging technologies in proton therapy. Acta Oncol 2011;50:838–50.
   PubMed Web of Science ®Google Scholar
• Mendenhall NP, Malyapa RS, Su Z, Yeung D, Mendenhall WM, Li Z. Proton therapy for head and neck cancer: Rationale, potential indications, practical considerations, and current clinical evidence. Acta Oncol 2011;50:763–71.
   PubMed Web of Science ®Google Scholar
• Liao Z, Lin SH, Cox JD. Status of particle therapy for lung cancer. Acta Oncol 2011;50:745–56.
   PubMed Web of Science ®Google Scholar
• Sørensen BS, Jens Overgaard J, Bassler N. In vitro RBE-LET dependence for multiple particle types. Acta Oncol 2011;50:757–62.
   PubMed Web of Science ®Google Scholar
• Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H, . Proton beams to replace photon beams in radical dose treatments. Acta Oncol 2003;42:800–8.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Montelius A. Proton beam therapy – Do we need the randomised trials and can we do them?Radiother Oncol 2007;83:105–9.
   PubMed Web of Science ®Google Scholar
• Bekelman JE, Han SM. The body of evidence for advanced technology in radiation oncology. J Natl Cancer Inst 2013; 105:6–7.
   PubMedGoogle Scholar
• Radu C, Norrlid O, Brændengen M, Hansson K, Isacsson U, Glimelius B. Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients. Acta Oncol 2013;53:this issue.
   Google Scholar
• Cheng CW, Das IJ, Srivastava SP, Zhao L, Wolanski M, Simmons J, . Dosimetric comparison between proton and photon beams in the moving gap region in cranio-spinal irradiation (CSI). Acta Oncol 2013;53:this issue.
   Google Scholar
• Fogliata A, Scorsetti M, Navarria P, Catalano M, Clivio A, Cozzi L, . Dosimetric comparison between VMAT with different dose calculation algorithms and protons for soft tissue sarcoma radiotherapy. Acta Oncol 2013;53:this issue.
   Google Scholar
• Brower JV, Indelicato DJ , Aldana PR , Sandler E, Rotondo R, Mendenhall NP, . A treatment planning comparison of highly conformal radiation therapy for pediatric low-grade brainstem gliomas. Acta Oncol 2013;53:this issue.
   Google Scholar
• Henderson RH, Hoppe BS, Marcus Jr RB, Mendenhall WM, Nichols RC, Zuofeng Li Z, . Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials. Acta Oncol 2013;53:this issue.
   Google Scholar
• Malik R, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer: Urinary outcomes for men with high International Prostate Symptom Scores (IPSS). Int J Radiat Oncol Biol Phys 2011;80:1080–6.
   PubMed Web of Science ®Google Scholar
• Talcott, JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, . Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 2010;303:1046–53.
   PubMed Web of Science ®Google Scholar
• Kil WJ, Nichols Jr RC, Hoppe BS, Morris CG, Marcus Jr RB, Mendenhall W, . Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression. Acta Oncol 2013;53:this issue.
   Google Scholar
• Yoon M, Ahn SH, Kim J, Shin DH, Park SY, Lee SB, . Radiation-induced cancers from modern radiotherapy techniques: Intensity-modulated radiotherapy versus proton therapy. Int J Radiat Oncol Biol Phys 2010;77:1477–85.
   PubMed Web of Science ®Google Scholar
• Shin, D, Yoon M, Kwak J, Shin J, Lee SB, Park SY, . Secondary neutron doses for several beam configurations for proton therapy. Int J Radiat Oncol Biol Phys 2009;74:260–5.
   PubMed Web of Science ®Google Scholar
• Wroe A, Clasie B, Kooy H, Flanz J, Schulte R, Rosenfeld A. Out-of-field dose equivalents delivered by passively scattered therapeutic proton beams for clinically relevant field configurations. Int J Radiat Oncol Biol Phys 2009;73:306–13.
   PubMed Web of Science ®Google Scholar
• Oermann EK, Suy S, Hanscom HN, Kim JS, Lei S, Yu X, . Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol Oncol 2011;4:12.
   PubMed Web of Science ®Google Scholar
• Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006;65:1–7.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES. The Bragg peak of proton beams for treatment of uveal melanoma. Int Ophthalmol Clin 1980;20:123–33.
   PubMedGoogle Scholar
• Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: Preliminary results of a phase II trial. Gastroenterology 2004;127(5 Suppl 1):189–93.
   Web of Science ®Google Scholar
• Bush DA. Proton radiation therapy for lung cancer: Is there enough evidence?Oncology (Williston Park) 2010;24:1052–7.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Cho KH, Pyo H, Lee KH, Moon SH, Kim TH, . A phase II study of hypofractionated proton therapy for prostate cancer. Acta Oncol 2013;53:this issue.
   PubMedGoogle Scholar
• Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer?Int J Radiat Oncol Biol Phys 2003;56:1093–104.
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, . A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:11–8.
   PubMed Web of Science ®Google Scholar
• Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, . Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;69:1084–9.
   PubMed Web of Science ®Google Scholar
• Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099–105.
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, . Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
   PubMed Web of Science ®Google Scholar
• Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, . Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18:3904–11.
   PubMed Web of Science ®Google Scholar
• Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, . Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005;294:1233–9.
   PubMed Web of Science ®Google Scholar
• Dasu A, Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol 2012;51:963–74.
   PubMed Web of Science ®Google Scholar
• Combs SE, Welzel T, Habermehl D, Rieken S, Dittmar JO, Kessel K, . Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and DOTATOC-PET. Acta Oncol 2013;53:this issue.
   Google Scholar
• Weber DC, Schneider R, Goitein G, Koch T, Ares C, Geismar JH, . Spot scanning based proton therapy for intracranial meningioma: Long-term results from the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 2012;83:865–71.
   PubMed Web of Science ®Google Scholar
• Hopfgartner J, Stock M, Georg D, Knäusl B. Dosimetric robustness of IMPT treatment plans with respect to inter-fractional set-up uncertainties: Impact of various beam arrangements for cranial targets. Acta Oncol 2013;53:this issue.
   Google Scholar
• Thörnqvist S, Muren LP, Bentzen L, Hysing L, Høyer M, Grau C, . Degradation of target coverage due to inter-fraction motion during intensity-modulated proton therapy of prostate and elective targets. Acta Oncol 2013; 53:this issue.
   Google Scholar
• Suit H. The Gray Lecture2001: Coming technical advances in radiation oncology.Int J Radiat Oncol Biol Phys 2002;53:798–809.
   Web of Science ®Google Scholar
• De Ruysscher D, Mark Lodge M, Jones B, Brada M, Munro A, Jefferson T, . Charged particles in radiotherapy: A 5-year update of a systematic review. Radiother Oncol 2012;103:5–7.
   PubMed Web of Science ®Google Scholar
• Allen AM, Pawlicki T, Dong L, Fourkal E, Buyyounouski M, Cengel K, . An evidence based review of proton beam therapy: The report of ASTRO’s emerging technology committee. Radiother Oncol 2012;103:8–11.
   PubMed Web of Science ®Google Scholar
• La Tessa C, Berger T, Kaderka R, Schardt D, Körner C, Ramm U, . Out-of-field dose studies with an anthropomorphic phantom: Comparison of X-rays and particle therapy treatments. Radiother Oncol 2012;105:133–8.
   PubMed Web of Science ®Google Scholar
• Stuschke M, Kaiser A, Pöttgen C, Lübcke W, Farr J. Potentials of robust intensity modulated scanning proton plans for locally advanced lung cancer in comparison to intensity modulated photon plans. Radiother Oncol 2012; 104:45–51.
   PubMed Web of Science ®Google Scholar
• Jensen AD, Nikoghosyan A, Ellerbrock M, Ecker S, Debus J, Münter MW. Re-irradiation with scanned charged particle beams in recurrent tumours of the head and neck: Acute toxicity and feasibility. Radiother Oncol 2011;101:383–7.
   PubMed Web of Science ®Google Scholar